{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:58:21Z","timestamp":1781312301199,"version":"3.54.1"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113157","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T06:42:28Z","timestamp":1726468948000},"page":"113157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"PB","title":["Current status of nucleic acid therapy and its new progress in cancer treatment"],"prefix":"10.1016","volume":"142","author":[{"given":"Wenting","family":"Lou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0005","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ydbio.2004.11.028","article-title":"Friedrich Miescher and the discovery of DNA","volume":"278","author":"Dahm","year":"2005","journal-title":"Dev. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.83.2.89","article-title":"Studies on the chemical nature of the substance inducing transformation of pneumococcal types: II. Effect of desoxyribonuclease on the biological activity of the transforming substance","volume":"83","author":"McCarty","year":"1946","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.bi.49.070180.000245","article-title":"A Pursuit of a Hobby","volume":"49","author":"Ochoa","year":"1980","journal-title":"Annu. Rev. Biochem"},{"key":"10.1016\/j.intimp.2024.113157_b0020","doi-asserted-by":"crossref","unstructured":"C.P. Kyriacou, As good as it gets: An Introduction to Genetic Analysis (7th Edn) by AJF Griffiths, JH Miller, DT Suzuki, RC Lewontin and WM Gelbart, Trends Genet., 2000, 16(8): 368.","DOI":"10.1016\/S0168-9525(00)02046-1"},{"issue":"13","key":"10.1016\/j.intimp.2024.113157_b0025","doi-asserted-by":"crossref","first-page":"R526","DOI":"10.1016\/j.cub.2015.05.032","article-title":"Who discovered messenger RNA?","volume":"25","author":"Cobb","year":"2015","journal-title":"Curr. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2024.113157_b0035","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1089\/hum.1995.6.9-1129","article-title":"Nonviral gene therapy: the promise of genes as pharmaceutical products","volume":"6","author":"Ledley","year":"1995","journal-title":"Hum. Gene Ther."},{"issue":"12","key":"10.1016\/j.intimp.2024.113157_b0040","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1039\/C5BM00198F","article-title":"Biomaterials for mRNA delivery","volume":"3","author":"Islam","year":"2015","journal-title":"Biomater. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2024.113157_b0045","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.intimp.2024.113157_b0050","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1208\/aapsj070109","article-title":"DNA-based therapeutics and DNA delivery systems: a comprehensive review","volume":"7","author":"Patil","year":"2005","journal-title":"AAPS J."},{"key":"10.1016\/j.intimp.2024.113157_b0055","series-title":"Small Molecules: Controlling Cell Fate and Function, In Situ Tissue Regeneration","first-page":"87","author":"Lu","year":"2016"},{"key":"10.1016\/j.intimp.2024.113157_b0060","series-title":"Medical Biotechnology: Techniques and Applications, Omics Technologies and Bio-engineering","first-page":"449","author":"Pham","year":"2018"},{"issue":"8","key":"10.1016\/j.intimp.2024.113157_b0065","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrd.2016.29","article-title":"Small molecules, big targets: drug discovery faces the protein\u2013protein interaction challenge","volume":"15","author":"Scott","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.intimp.2024.113157_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103366","article-title":"Trends in small molecule drug properties: a developability molecule assessment perspective","volume":"27","author":"Agarwal","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"16","key":"10.1016\/j.intimp.2024.113157_b0075","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1021\/acs.chemrev.7b00678","article-title":"Intracellular delivery by membrane disruption: mechanisms, strategies, and concepts","volume":"118","author":"Stewart","year":"2018","journal-title":"Chem. Rev."},{"key":"10.1016\/j.intimp.2024.113157_b0080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.omtn.2019.12.004","article-title":"Improved nucleic acid therapy with advanced nanoscale biotechnology","volume":"19","author":"Weng","year":"2020","journal-title":"Mol. Ther.-Nucleic Acids"},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43586-022-00104-y","article-title":"Nanodelivery of nucleic acids","volume":"2","author":"Mendes","year":"2022","journal-title":"Nat. Rev. Methods Primers"},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(21)00581-7","article-title":"The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"23","author":"Alvarez","year":"2022","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.intimp.2024.113157_b0095","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10053","key":"10.1016\/j.intimp.2024.113157_b0100","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0140-6736(16)31679-8","article-title":"Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Forouzanfar","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.intimp.2024.113157_b0105","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1016\/S2352-3018(19)30196-1","article-title":"Global, regional, and national incidence, prevalence, and mortality of HIV, 1980\u20132017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017","volume":"6","author":"Frank","year":"2019","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.intimp.2024.113157_b0110","first-page":"576","article-title":"Genomes, proteomes, and the central dogma","volume":"4","author":"Franklin","year":"2011","journal-title":"Circulation: Cardiovasc. Genet."},{"issue":"6","key":"10.1016\/j.intimp.2024.113157_b0115","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1021\/acs.jproteome.1c00074","article-title":"Protein\u2013DNA\/RNA interactions: an overview of investigation methods in the-omics era","volume":"20","author":"Cozzolino","year":"2021","journal-title":"J. Proteome Res."},{"issue":"11","key":"10.1016\/j.intimp.2024.113157_b0120","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","article-title":"Mutation clearance after transplantation for myelodysplastic syndrome","volume":"379","author":"Duncavage","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/annonc\/mdu378","article-title":"Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials","volume":"26","author":"Sorich","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2024.113157_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-017-0450-0","article-title":"Advances in the delivery of RNA therapeutics: from concept to clinical reality","volume":"9","author":"Kaczmarek","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.intimp.2024.113157_b0135","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","article-title":"Strategies, design, and chemistry in siRNA delivery systems","volume":"144","author":"Dong","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.intimp.2024.113157_b0140","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.biomaterials.2017.11.046","article-title":"DNA nanoparticles for ophthalmic drug delivery","volume":"157","author":"de Vries","year":"2018","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.intimp.2024.113157_b0145","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tips.2020.08.004","article-title":"Paving the road for RNA therapeutics","volume":"41","author":"Dammes","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2024.113157_b0150","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2024.113157_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113834","article-title":"Nucleic acid delivery for therapeutic applications","volume":"178","author":"Gupta","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.intimp.2024.113157_b0160","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejps.2019.03.027","article-title":"Oral delivery of non-viral nucleic acid-based therapeutics-do we have the guts for this?","volume":"133","author":"O'Driscoll","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0165","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrc2966","article-title":"RNA interference in the clinic: challenges and future directions","volume":"11","author":"Pecot","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"11\u201312","key":"10.1016\/j.intimp.2024.113157_b0170","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.drudis.2008.03.014","article-title":"Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?","volume":"13","author":"Rayburn","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.intimp.2024.113157_b0175","article-title":"The role of nucleases and nucleic acid editing enzymes in the regulation of self-nucleic acid sensing","volume":"12","author":"Santa","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113157_b0180","article-title":"Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant","volume":"2010","author":"Jin","year":"2010","journal-title":"Biomed Res. Int."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0185","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/nat.2021.0085","article-title":"Challenges and opportunities for nucleic acid therapeutics","volume":"32","author":"Corey","year":"2022","journal-title":"Nucleic Acid Therap."},{"issue":"19","key":"10.1016\/j.intimp.2024.113157_b0190","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.3390\/cancers13195002","article-title":"Nucleic acid drugs\u2014current status, issues, and expectations for exosomes","volume":"13","author":"Yamada","year":"2021","journal-title":"Cancers"},{"issue":"6287","key":"10.1016\/j.intimp.2024.113157_b0195","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2024.113157_b0200","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nsmb1226","article-title":"Potent effect of target structure on microRNA function","volume":"14","author":"Long","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113157_b0205","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4062\/biomolther.2013.085","article-title":"Nucleic acid aptamers: New methods for selection, stabilization, and application in biomedical science","volume":"21","author":"Kong","year":"2013","journal-title":"Biomol. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2024.113157_b0210","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0215","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cells9010137","article-title":"RNA-based therapeutics: from antisense oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells"},{"issue":"98","key":"10.1016\/j.intimp.2024.113157_b0220","first-page":"151","article-title":"State-of-the-art human gene therapy: Part II. Gene therapy strategies and applications","volume":"18","author":"Wang","year":"2014","journal-title":"Discov. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/tnsci-2017-0001","article-title":"ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy","volume":"8","author":"Ottesen","year":"2017","journal-title":"Transl. Neurosci."},{"issue":"6387","key":"10.1016\/j.intimp.2024.113157_b0230","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1126\/science.aaq0179","article-title":"Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6","volume":"360","author":"Gootenberg","year":"2018","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.intimp.2024.113157_b0235","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1073\/pnas.1402353111","article-title":"Specific inhibition of diverse pathogens in human cells by synthetic microRNA-like oligonucleotides inferred from RNAi screens","volume":"111","author":"Franceschini","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2024.113157_b0240","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/nar\/gks1191","article-title":"Improved nucleic acid descriptors for siRNA efficacy prediction","volume":"41","author":"Sciabola","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.113157_b0245","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/path.5664","article-title":"Advancing drug discovery using the power of the human genome","volume":"254","author":"Heilbron","year":"2021","journal-title":"J. Pathol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113157_b0250","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-019-0127-1","article-title":"Benefits and limitations of genome-wide association studies","volume":"20","author":"Tam","year":"2019","journal-title":"Nat. Rev. Genet."},{"issue":"17","key":"10.1016\/j.intimp.2024.113157_b0255","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-customized oligonucleotide therapy for a rare genetic disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.113157_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2022.02.016","article-title":"COVID-19 mRNA vaccines: Platforms and current developments","author":"Szab\u00f3","year":"2022","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2024.113157_b0265","first-page":"294","article-title":"Gene therapy","volume":"38","author":"Keeler","year":"1947","journal-title":"J. Hered."},{"issue":"3993","key":"10.1016\/j.intimp.2024.113157_b0270","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1126\/science.173.3993.195","article-title":"Reservations concerning gene therapy","volume":"173","author":"Fox","year":"1971","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.intimp.2024.113157_b0275","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1073\/pnas.74.10.4370","article-title":"Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation","volume":"74","author":"Paterson","year":"1977","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0280","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2024.113157_b0285","first-page":"14","article-title":"Fomivirsen approved for CMV retinitis","volume":"4","author":"Roehr","year":"1998","journal-title":"J. Int. Assoc. Physicians AIDS Care"},{"issue":"4949","key":"10.1016\/j.intimp.2024.113157_b0290","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.intimp.2024.113157_b0295","first-page":"1397","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res."},{"issue":"6669","key":"10.1016\/j.intimp.2024.113157_b0300","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"6893","key":"10.1016\/j.intimp.2024.113157_b0305","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/418038a","article-title":"RNA interference in adult mice","volume":"418","author":"McCaffrey","year":"2002","journal-title":"Nature"},{"issue":"7291","key":"10.1016\/j.intimp.2024.113157_b0310","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.intimp.2024.113157_b0315","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0320","doi-asserted-by":"crossref","first-page":"12383","DOI":"10.1080\/21655979.2021.2003666","article-title":"Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery","volume":"12","author":"Wu","year":"2021","journal-title":"Bioengineered"},{"issue":"4","key":"10.1016\/j.intimp.2024.113157_b0325","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1021\/acs.jmedchem.2c01337","article-title":"Metabolically stable anomeric linkages containing GalNAc\u2013siRNA conjugates: an interplay among ASGPR, glycosidase, and RISC pathways","volume":"66","author":"Kandasamy","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2024.113157_b0330","first-page":"1","article-title":"Antibody\u2013drug conjugate (ADC) clinical pipeline: a review","author":"Sassoon","year":"2013","journal-title":"Antibody-Drug Conjug."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0335","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1021\/acs.molpharmaceut.3c00735","article-title":"Unleashing the potential: designing antibody-targeted lipid nanoparticles for industrial applications with CMC considerations and clinical outlook","volume":"21","author":"Wang","year":"2024","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.intimp.2024.113157_b0340","first-page":"347","article-title":"Antisense oligonucleotides: basic concepts and mechanisms","volume":"1","author":"Dias","year":"2002","journal-title":"Mol. Cancer Ther."},{"issue":"15","key":"10.1016\/j.intimp.2024.113157_b0345","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202002022","article-title":"Therapeutic RNA delivery for COVID and other diseases","volume":"10","author":"Dobrowolski","year":"2021","journal-title":"Adv. Healthc. Mater."},{"issue":"17","key":"10.1016\/j.intimp.2024.113157_b0350","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2024.113157_b0355","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"issue":"9","key":"10.1016\/j.intimp.2024.113157_b0360","doi-asserted-by":"crossref","DOI":"10.7150\/jca.11735","article-title":"Argonaute 2: a novel rising star in cancer research","volume":"6","author":"Ye","year":"2015","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0365","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular mechanisms of antisense oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0370","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2024.113157_b0375","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113157_b0380","article-title":"The powerful world of antisense oligonucleotides: From bench to bedside","volume":"11","author":"Quemener","year":"2020","journal-title":"Wiley Interdiscip. Rev.: RNA"},{"issue":"3","key":"10.1016\/j.intimp.2024.113157_b0385","first-page":"890","article-title":"Pharmacokinetic properties of 2\u2032-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats","volume":"296","author":"Geary","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2024.113157_b0390","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1039\/c1cs15048k","article-title":"Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals","volume":"40","author":"Campbell","year":"2011","journal-title":"Chem. Soc. Rev."},{"issue":"9","key":"10.1016\/j.intimp.2024.113157_b0395","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/nar\/30.9.1911","article-title":"Design of antisense oligonucleotides stabilized by locked nucleic acids","volume":"30","author":"Kurreck","year":"2002","journal-title":"Nucleic Acids Res."},{"issue":"36","key":"10.1016\/j.intimp.2024.113157_b0400","doi-asserted-by":"crossref","first-page":"6397","DOI":"10.1016\/S0040-4039(97)01436-6","article-title":"Highly efficient [2+1] cycloaddition reactions of a 1-seleno-2-silylethene to 2-phosphonoacrylates: synthesis of novel functionalized cyclopropanephosphonic acid esters","volume":"38","author":"Yamazaki","year":"1997","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.intimp.2024.113157_b0405","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1039\/a708608c","article-title":"LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition","volume":"4","author":"Singh","year":"1998","journal-title":"Chem. Commun."},{"issue":"8","key":"10.1016\/j.intimp.2024.113157_b0410","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1039\/D0CS01430C","article-title":"Recent progress in non-native nucleic acid modifications","volume":"50","author":"McKenzie","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"51","key":"10.1016\/j.intimp.2024.113157_b0415","doi-asserted-by":"crossref","first-page":"48650","DOI":"10.1021\/acsomega.3c07618","article-title":"Evaluation of chemically modified nucleic acid analogues for splice switching application","volume":"8","author":"Le","year":"2023","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0420","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40291-021-00573-z","article-title":"Reduction of off-target effects of gapmer antisense oligonucleotides by oligonucleotide extension","volume":"26","author":"Yasuhara","year":"2022","journal-title":"Mol. Diagn. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0425","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000323","article-title":"Antisense oligonucleotides: a primer","volume":"5","author":"Scoles","year":"2019","journal-title":"Neurol. Genet."},{"issue":"9","key":"10.1016\/j.intimp.2024.113157_b0430","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ymthe.2019.06.009","article-title":"Enhanced potency of GalNAc-conjugated antisense oligonucleotides in hepatocellular cancer models","volume":"27","author":"Kim","year":"2019","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2024.113157_b0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"issue":"29","key":"10.1016\/j.intimp.2024.113157_b0440","doi-asserted-by":"crossref","first-page":"1705328","DOI":"10.1002\/adma.201705328","article-title":"Advances in biomaterials for drug delivery","volume":"30","author":"Fenton","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.intimp.2024.113157_b0445","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00018-018-2935-4","article-title":"mRNA as novel technology for passive immunotherapy","volume":"76","author":"Schlake","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.intimp.2024.113157_b0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.974433","article-title":"How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113157_b0455","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","article-title":"Comparison of DNA and mRNA vaccines against cancer","volume":"25","author":"Jahanafrooz","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0460","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.intimp.2024.113157_b0465","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2014developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2024.113157_b0470","doi-asserted-by":"crossref","unstructured":"N. Josephson, The hemophilias and their clinical management, Hematology 2013, the American Society of Hematology Education Program Book, 2013(1) (2013) 261-267.","DOI":"10.1182\/asheducation-2013.1.261"},{"issue":"21","key":"10.1016\/j.intimp.2024.113157_b0475","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2024.113157_b0480","series-title":"Symp Soc Exp Biol.","article-title":"On protein synthesis","author":"Crick","year":"1958"},{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0485","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14760584.2015.986104","article-title":"Lipid-based mRNA vaccine delivery systems","volume":"14","author":"Midoux","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.intimp.2024.113157_b0490","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.912594","article-title":"Nanodrugs targeting T cells in tumor therapy","volume":"13","author":"Haist","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0495","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1101\/gad.13.2.139","article-title":"RNAi and double-strand RNA","volume":"13","author":"Sharp","year":"1999","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.intimp.2024.113157_b0500","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.tcb.2005.03.006","article-title":"RNA silencing and genome regulation","volume":"15","author":"Almeida","year":"2005","journal-title":"Trends Cell Biol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0505","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cell.2007.04.037","article-title":"Molecular basis for target RNA recognition and cleavage by human RISC","volume":"130","author":"Ameres","year":"2007","journal-title":"Cell"},{"issue":"2\u20133","key":"10.1016\/j.intimp.2024.113157_b0510","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","article-title":"RNAi therapeutics: principles, prospects and challenges","volume":"59","author":"Aagaard","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0515","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2004.07.007","article-title":"Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs","volume":"15","author":"Meister","year":"2004","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0520","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2004.06.017","article-title":"Single processing center models for human Dicer and bacterial RNase III","volume":"118","author":"Zhang","year":"2004","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.intimp.2024.113157_b0525","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0530","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0535","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular mechanisms and biological functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int. J. Biomed. Sci."},{"issue":"20","key":"10.1016\/j.intimp.2024.113157_b0540","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1038\/sj.emboj.7600385","article-title":"MicroRNA genes are transcribed by RNA polymerase II","volume":"23","author":"Lee","year":"2004","journal-title":"EMBO J."},{"issue":"6956","key":"10.1016\/j.intimp.2024.113157_b0545","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature01957","article-title":"The nuclear RNase III Drosha initiates microRNA processing","volume":"425","author":"Lee","year":"2003","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.intimp.2024.113157_b0550","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2144\/000112792","article-title":"RNAi mechanisms and applications","volume":"44","author":"Kim","year":"2008","journal-title":"Biotechniques"},{"key":"10.1016\/j.intimp.2024.113157_b0555","first-page":"4","article-title":"siRNA versus miRNA as therapeutics for gene silencing","author":"Lam","year":"2015","journal-title":"Mol. Ther.-Nucleic Acids"},{"issue":"4","key":"10.1016\/j.intimp.2024.113157_b0560","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cell.2005.10.022","article-title":"Human RISC couples microRNA biogenesis and posttranscriptional gene silencing","volume":"123","author":"Gregory","year":"2005","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.intimp.2024.113157_b0565","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/cr.2016.22","article-title":"saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription","volume":"26","author":"Portnoy","year":"2016","journal-title":"Cell Res."},{"issue":"24","key":"10.1016\/j.intimp.2024.113157_b0570","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1038\/s41388-018-0126-2","article-title":"Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer","volume":"37","author":"Reebye","year":"2018","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.intimp.2024.113157_b0575","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41434-019-0095-2","article-title":"Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA","volume":"26","author":"Blakney","year":"2019","journal-title":"Gene Ther."},{"issue":"6","key":"10.1016\/j.intimp.2024.113157_b0580","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.biotechadv.2015.02.008","article-title":"Current approaches in SELEX: An update to aptamer selection technology","volume":"33","author":"Darmostuk","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.intimp.2024.113157_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2021.122274","article-title":"Capture-SELEX for aptamer selection: A short review","volume":"229","author":"Lyu","year":"2021","journal-title":"Talanta"},{"key":"10.1016\/j.intimp.2024.113157_b0590","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fgene.2012.00234","article-title":"Current progress of RNA aptamer-based therapeutics","volume":"3","author":"Zhou","year":"2012","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0595","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.113157_b0605","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.biopha.2004.01.003","article-title":"Targeted nucleic acid delivery into tumors: new avenues for cancer therapy","volume":"58","author":"Wagner","year":"2004","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2024.113157_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115052","article-title":"A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics","author":"Ranjbar","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.intimp.2024.113157_b0615","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003495-199957030-00010","article-title":"Fomivirsen","volume":"57","author":"Perry","year":"1999","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.intimp.2024.113157_b0620","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0625","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/07357907.2018.1550090","article-title":"c-MYB and DMTF1 in cancer","volume":"37","author":"Fry","year":"2019","journal-title":"Cancer Invest."},{"key":"10.1016\/j.intimp.2024.113157_b0630","unstructured":"C-myb Antisense Oligonucleotide G4460. Available online: https:\/\/ncit.nci.nih.gov\/ncitbrowser\/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C1541 (accessed on 20 January 2024)."},{"issue":"9","key":"10.1016\/j.intimp.2024.113157_b0635","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1073\/pnas.86.9.3379","article-title":"An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines","volume":"86","author":"Anfossi","year":"1989","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2024.113157_b0640","first-page":"1150","article-title":"Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study","volume":"99","author":"Luger","year":"2002","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113157_b0645","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/sj.cdd.4400781","article-title":"The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability","volume":"7","author":"Harris","year":"2000","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.intimp.2024.113157_b0650","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.180002","article-title":"Targeting BCL-2 regulated apoptosis in cancer","volume":"8","author":"Campbell","year":"2018","journal-title":"Open Biol."},{"key":"10.1016\/j.intimp.2024.113157_b0655","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10495-008-0300-z","article-title":"Bcl2 family proteins in carcinogenesis and the treatment of cancer","volume":"14","author":"Frenzel","year":"2009","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0660","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00129039-200503000-00002","article-title":"Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer","volume":"13","author":"Morris","year":"2005","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0665","first-page":"425","article-title":"Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia","volume":"101","author":"Marcucci","year":"2003","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"13","key":"10.1016\/j.intimp.2024.113157_b0670","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/bloodadvances.2021004233","article-title":"Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)","volume":"5","author":"Walker","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2024.113157_b0675","unstructured":"Clinical Trial ofBP1001in Combination With With Venetoclax Plus Decitabine in AML. Available online: https:\/\/clinicaltrials.gov\/study\/NCT02781883?term=BP1001&rank=4(accessed on 22 January 2024)."},{"issue":"4","key":"10.1016\/j.intimp.2024.113157_b0680","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/S2352-3026(18)30021-8","article-title":"Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1\/1b trial","volume":"5","author":"Ohanian","year":"2018","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.intimp.2024.113157_b0685","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s10555-020-09915-5","article-title":"Molecular epidemiology and diagnostics of KRAS mutations in human cancer","volume":"39","author":"Timar","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"10","key":"10.1016\/j.intimp.2024.113157_b0690","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3390\/pharmaceutics13101638","article-title":"RNAi-based approaches for pancreatic cancer therapy","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"issue":"51","key":"10.1016\/j.intimp.2024.113157_b0695","doi-asserted-by":"crossref","first-page":"20723","DOI":"10.1073\/pnas.1314307110","article-title":"Mutant KRAS is a druggable target for pancreatic cancer","volume":"110","author":"Zorde Khvalevsky","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"27","key":"10.1016\/j.intimp.2024.113157_b0700","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.intimp.2024.113157_b0705","doi-asserted-by":"crossref","unstructured":"A.M. Varghese, C. Ang, C.J. Dimaio, M.M. Javle, M. Gutierrez, N. Yarom, S.M. Stemmer, T. Golan, R. Geva, V. Semenisty, et al, A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT), 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS4672"},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00944-9","article-title":"Targeting EphA2 in cancer","volume":"13","author":"Xiao","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"15","key":"10.1016\/j.intimp.2024.113157_b0715","doi-asserted-by":"crossref","first-page":"6910","DOI":"10.1158\/0008-5472.CAN-05-0530","article-title":"Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery","volume":"65","author":"Landen","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2024.113157_b0720","doi-asserted-by":"crossref","unstructured":"A. Naing, G. Lopez-Berestein, S. Fu, A.M. Tsimberidou, S. Pant, S.A. Piha-Paul, F. Janku, D.S. Hong, S. Sulovic, X. Meng, et al, EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial, 2017.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS2604"},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0725","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad059","article-title":"Codelivery of TGF\u03b2 and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint Inhibitors","volume":"6","author":"Kim","year":"2024","journal-title":"NAR Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0730","first-page":"114","article-title":"How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market","volume":"30","author":"Bonneau","year":"2019","journal-title":"Ejifcc"},{"key":"10.1016\/j.intimp.2024.113157_b0735","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.47","article-title":"Mir-34: a new weapon against cancer?","volume":"3","author":"Misso","year":"2014","journal-title":"Mol. Ther.-Nucleic Acids"},{"issue":"6","key":"10.1016\/j.intimp.2024.113157_b0740","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/10408360290795574","article-title":"CD44 in cancer","volume":"39","author":"Naor","year":"2002","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2024.113157_b0745","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm.2284","article-title":"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"17","author":"Liu","year":"2011","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.113157_b0750","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113157_b0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-023-00449-w","article-title":"Advances of mRNA vaccine in tumor: a maze of opportunities and challenges","volume":"11","author":"Yuan","year":"2023","journal-title":"Biomarker Res."},{"issue":"20","key":"10.1016\/j.intimp.2024.113157_b0760","doi-asserted-by":"crossref","first-page":"19550","DOI":"10.1021\/acsnano.3c05635","article-title":"mRNA cancer vaccines: construction and boosting strategies","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.intimp.2024.113157_b0765","article-title":"FDA grants breakthrough designation to mRNA vaccine for resected melanoma","author":"Conroy","year":"2023","journal-title":"Cancer Network"},{"key":"10.1016\/j.intimp.2024.113157_b0770","unstructured":"C. Seymour, Combination of mRNA-4157 with pembrolizumab improves survival in melanoma."},{"key":"10.1016\/j.intimp.2024.113157_b0775","first-page":"1","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","author":"Rojas","year":"2023","journal-title":"Nature"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924016795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924016795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T05:57:02Z","timestamp":1734069422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924016795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":155,"alternative-id":["S1567576924016795"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113157","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status of nucleic acid therapy and its new progress in cancer treatment","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113157"}}